Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice.
Conjugated linoleic acids (CLAs) and n-3 polyunsaturated fatty acids (PUFAs) improve insulin sensitivity in insulin-resistant rodents. However, the effects of these fatty acids on insulin secretion are not known but are of importance to completely understand their influence on glucose homeostasis. We therefore examined islet function after dietary supplementation consisting of 1% CLAs in combination with 1% n-3 enriched PUFAs for 12 wk to mice on a normal diet and to insulin-resistant mice fed a high-fat diet (58% fat). In the mice fed a normal diet, CLA/PUFA supplementation resulted in insulin resistance associated with low plasma adiponectin levels and low body fat content. Intravenous and oral glucose tolerance tests revealed a marked increase in insulin secretion, which nevertheless was insufficient to counteract the insulin resistance, resulting in glucose intolerance. In freshly isolated islets from mice fed the normal diet, both basal and glucose-stimulated insulin secretion were adaptively augmented by CLA/PUFA, and at a high glucose concentration this was accompanied by elevated glucose oxidation. In contrast, in high-fat-fed mice, CLA/PUFA did not significantly affect insulin secretion, insulin resistance, or glucose tolerance. It is concluded that dietary supplementation of CLA/PUFA in mice fed the normal diet augments insulin secretion, partly because of increased islet glucose oxidation, but that this augmentation is insufficient to counterbalance the induction of insulin resistance, resulting in glucose intolerance. Furthermore, the high-fat diet partly prevents the deleterious effects of CLA/PUFA, but this dietary supplementation was not able to counteract high-fat-diet-induced insulin resistance.
Winzell
Maria Sörhede
MS
Dept. of Clinical Sciences, Medicine, Lund University, BMC, B11, SE-221 84 Lund, Sweden. Maria.Sorhede_Winzell@med.lu.se
Pacini
Giovanni
G
Ahrén
Bo
B
D000284:Administration, Oral; D000818:Animals; D002478:Cells, Cultured; D004041:Dietary Fats / Q000378:metabolism*; D019587:Dietary Supplements; D004338:Drug Combinations; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D005947:Glucose / Q000378:metabolism; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance / Q000502:physiology*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism*; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL
D004041:Dietary Fats; D004338:Drug Combinations; D015525:Fatty Acids, Omega-3; D007328:Insulin; D044243:Linoleic Acids, Conjugated; D005947:Glucose